title: [Cardio-circulatory arrest with mifepristone sulprostone combination for pregnancy interruption].
authors.forename: F
authors.initials: F
authors.lastname: Sorbette
authors.forename: M
authors.initials: M
authors.lastname: Delay
authors.forename: M
authors.initials: M
authors.lastname: Genestal
authors.forename: M F
authors.initials: MF
authors.lastname: Jorda
authors.forename: D
authors.initials: D
authors.lastname: Carrie
authors.forename: J L
authors.initials: JL
authors.lastname: Montastruc
authors.forename: B
authors.initials: B
authors.lastname: Catala
authors.forename: P
authors.initials: P
authors.lastname: Bernadet
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects*; D000032:Abortion, Therapeutic / Q000009:adverse effects; D015232:Dinoprostone / Q000009:adverse effects / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D006323:Heart Arrest / Q000139:chemically induced*; D006801:Humans; D015735:Mifepristone / Q000009:adverse effects*; D011247:Pregnancy
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D015735:Mifepristone; C016767:sulprostone; D015232:Dinoprostone
vernacular_title: Arrêt cardio-circulatoire au cours de l'association mifépristone-sulprostone pour interruption de grossesse.